🔗 Share this article

While the US proceeds with unprecedented changes to its immunization schedules, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccines in the pandemic and has focused upon possible fatalities following COVID-19 vaccination in her brief tenure at the FDA.

Scheduled Overhauls to Childhood Vaccine Schedule

Public health authorities planned to reveal radical revisions to the pediatric vaccination calendar earlier this month, bringing the US with the Danish vaccine program, sources say – a significant shift that would place the US out of step with many the world with no evidence for benefit. The announcement has been postponed until the new year.

Instead of the director of the vaccine center, Høeg is set to speak at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

A Shift at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon rolling back already-approved immunizations at the FDA.

Høeg has frequently advocated for halting some pediatric immunization guidelines in the US to become more similar to Denmark's approach, a society with nationalized medicine and a population approximately the population of Wisconsin’s.

To date statements, she has persisted in emphasizing on immunizations – typically the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Background

The appointee has little discernible background in drug development, oversight or administrative roles, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a major agency. She is not an expert in industry regulation.”

Past heads of the center would “understand legal statutes and the science of medication creation”, commented Janet Woodcock. “Objectively, she lacks the type of experience that prior appointees who led the center have had.”

This division has an immense workload at the FDA, the former commissioner pointed out.

“The public just pays attention on the innovative therapies, but the generic program authorizes a multitude of generic drugs. There’s a biosimilars division, non-prescription drug unit and more, and every single one need to be looked after,” Dr. Woodcock noted. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant administrative component to the position, which manages in excess of 5,000 employees. “It’s a enormous management job, if you perform it correctly,” the former official concluded.

Agency Reaction and Disputed Policies

When asked about concerns about Dr. Høeg's qualifications and whether this selection represents more teamwork among regulatory chiefs on immunizations, a spokesperson stated that the “inquiries are based on inaccurate presumptions”.

“This background matches the functions of her job,” the representative explained, citing the time Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's new expedited review system, a controversial rapid drug-approval program that allegedly worried her former heads. “By what process are these drugs being selected for this voucher program? Who makes the choices?” Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he said, “the FDA looks to be trending towards laxer rules of pharmaceuticals, with the exception of immunizations.”

Public Track Record on Vaccines

With immunizations, Høeg has a clearer, if troubling, track record, some experts said. She released a research paper using unverified crowd-sourced reports to determine the incidence of myocarditis after COVID-19 immunization. She consulted for the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the incoming administration featured altering rules for new vaccines and ending “unnecessary” vaccines, she stated post-election on a audio program. At the FDA, Høeg has reportedly floated the idea of barring adolescent males from receiving Covid vaccines.

“She is an thorough ideologue who commences with her conclusions and tailors the evidence to fit the evidence in a highly deceptive, fraudulent manner,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Høeg became part of fellow skeptics, {like|